You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 29, 2024

Details for Patent: 9,468,747


✉ Email this page to a colleague

« Back to Dashboard


Title:Nasal drug products and methods of their use
Abstract: Drug products adapted for nasal delivery, comprising a pre-primed device filled with a pharmaceutical composition comprising an opioid receptor antagonist, are provided. Methods of treating opioid overdose or its symptoms with the inventive drug products are also provided.
Inventor(s): Crystal; Roger (Santa Monica, CA), Weiss; Michael Brenner (New York, NY)
Assignee: Opiant Pharmaceuticals, Inc. (Santa Monica, CA)
Filing Date:Nov 24, 2015
Application Number:14/950,707
Claims:1. A method of treatment of opioid overdose or a symptom thereof, comprising nasally administering to a patient in need thereof a dose of naloxone hydrochloride using a single-use, pre-primed device adapted for nasal delivery of a pharmaceutical composition to a patient by one actuation of said device into one nostril of said patient, having a single reservoir comprising a pharmaceutical composition which is an aqueous solution of about 100 .mu.L comprising: about 4 mg naloxone hydrochloride or a hydrate thereof; between about 0.2 mg and about 1.2 mg of an isotonicity agent; between about 0.005 mg and about 0.015 mg of a compound which is at least one of a preservative, a cationic surfactant, and a permeation enhancer; between about 0.1 mg and about 0.5 mg of a stabilizing agent; and an amount of an acid sufficient to achieve a pH of 3.5-5.5.

2. The method as recited in claim 1 wherein: the isotonicity agent is NaCl; the preservative is benzalkonium chloride; the stabilizing agent is disodium edetate; and the acid is hydrochloric acid.

3. The method of claim 2, wherein the aqueous solution comprises: about 4.4 mg naloxone hydrochloride dihydrate; about 0.74 mg NaCl; about 0.01 mg benzalkonium chloride; about 0.2 mg disodium edetate; and an amount of hydrochloric acid sufficient to achieve a pH of 3.5-5.5.

4. The method of claim 2, wherein said method is actuatable with one hand.

5. The method of claim 4, wherein the volume of said reservoir is not more than about 140 .mu.L.

6. The method of claim 5, wherein about 100 .mu.L of said aqueous solution in said reservoir is delivered to said patient in one actuation.

7. The method of claim 6, wherein the pharmaceutical composition which is an aqueous solution comprises about 4.4 mg naloxone hydrochloride dihydrate.

8. The method of claim 7, wherein the 90% confidence interval for dose delivered per actuation is .+-.about 2%.

9. The method of claim 7, wherein the 95% confidence interval for dose delivered per actuation is .+-.about 2.5%.

10. The method of claim 7, wherein the delivery time is less than about 25 seconds.

11. The method of claim 7, wherein the delivery time is less than about 20 seconds.

12. The method of claim 11, wherein upon nasal delivery of said pharmaceutical composition to said patient, less than about 20% of said pharmaceutical composition leaves the nasal cavity via drainage into the nasopharynx or externally.

13. The method of claim 12, wherein upon nasal delivery of said pharmaceutical composition to said patient, less than about 10% of said pharmaceutical composition leaves the nasal cavity via drainage into the nasopharynx or externally.

14. The method of claim 13, wherein upon nasal delivery of said pharmaceutical composition to said patient, less than about 5% of said pharmaceutical composition leaves the nasal cavity via drainage into the nasopharynx or externally.

15. The method of claim 11, wherein the plasma concentration versus time curve of said naloxone hydrochloride in said patient has a T.sub.max of between about 20 and about 30 minutes.

16. The method of claim 1, wherein said patient is an opioid overdose patient or a suspected opioid overdose patient.

17. The method of claim 16, wherein the patient exhibits one or more symptoms chosen from: respiratory depression, central nervous system depression, cardiovascular depression, altered level consciousness, miotic pupils, hypoxemia, acute lung injury, aspiration pneumonia, sedation, hypotension, unresponsiveness to stimulus, unconsciousness, stopped breathing; erratic or stopped pulse, choking or gurgling sounds, blue or purple fingernails or lips, slack or limp muscle tone, contracted pupils, and vomiting.

18. The method of claim 17, wherein the patient exhibits respiratory depression.

19. The method of claim 18, wherein said respiratory depression is caused by the illicit use of opioids, or by an accidental misuse of opioids during medical opioid therapy.

20. The method of claim 19, wherein said patient is free from respiratory depression for at least about 1 hour following treatment comprising delivery of said therapeutically effective amount of said opioid antagonist.

21. The method of claim 20, wherein said patient is free from respiratory depression for at least about 2 hours following treatment comprising delivery of said therapeutically effective amount of said opioid antagonist.

22. The method of claim 21, wherein said patient is free from respiratory depression for at least about 4 hours following treatment comprising delivery of said therapeutically effective amount of said opioid antagonist.

23. The method of claim 22, wherein said patient is free from respiratory depression for at least about 6 hours following treatment comprising delivery of said therapeutically effective amount of said opioid antagonist.

24. The method of claim 16, wherein said patient is in a lying, supine, or recovery position.

25. The method of claim 7, wherein said single actuation yields a naloxone plasma concentration of .gtoreq.0.2 ng/mL within 2.5 minutes in said patient.

26. The method of claim 7, wherein said single actuation yields a naloxone plasma concentration of .gtoreq.1 ng/mL within 5 minutes in said patient.

27. The method of claim 7, wherein said single actuation yields a naloxone plasma concentration of .gtoreq.3 ng/mL within 10 minutes in said patient.

28. The method of claim 3, wherein said single actuation yields a naloxone plasma concentration of .gtoreq.0.2 ng/mL within 2.5 minutes in said patient.

29. The method of claim 3, wherein said single actuation yields a naloxone plasma concentration of .gtoreq.1 ng/mL within 5 minutes in said patient.

30. A pharmaceutical formulation for intranasal administration comprising, in an aqueous solution of not more than about 140 .mu.L: about 4 mg naloxone hydrochloride or a hydrate thereof; between about 0.2 mg and about 1.2 mg of an isotonicity agent; between about 0.005 mg and about 0.015 mg of a compound which is at least one of a preservative, a cationic surfactant, and a permeation enhancer; between about 0.1 mg and about 0.5 mg of a stabilizing agent; an amount of an acid sufficient to achieve a pH of 3.5-5.5.

31. The pharmaceutical formulation as recited in claim 30, wherein the naloxone hydrochloride is provided as naloxone hydrochloride dihydrate.

32. The pharmaceutical formulation as recited in claim 30, wherein: the isotonicity agent is NaCl; the compound which is at least one of a preservative, a cationic surfactant, and a permeation enhancer is benzalkonium chloride; the stabilizing agent is disodium edetate; and the acid is hydrochloric acid.

33. The pharmaceutical formulation as recited in claim 31, wherein the aqueous solution comprises: about 4.4 mg naloxone hydrochloride dihydrate; about 0.74 mg NaCl; about 0.01 mg benzalkonium chloride; about 0.2 mg disodium edetate; and an amount of hydrochloric acid sufficient to achieve a pH of 3.5-5.5.

34. The pharmaceutical formulation of claim 30, which yields, when intranasally administered to a patient, a naloxone plasma concentration of .gtoreq.0.2 ng/mL within 2.5 minutes in said patient.

35. The pharmaceutical formulation of claim 30, which yields, when intranasally administered to a patient, a naloxone plasma concentration of .gtoreq.1 ng/mL within 5 minutes in said patient.

36. The pharmaceutical formulation of claim 30, which yields, when intranasally administered to a patient, a naloxone plasma concentration of .gtoreq.3 ng/mL within 10 minutes in said patient.

37. The pharmaceutical formulation of claim 33, which yields, when intranasally administered to a patient, a naloxone plasma concentration of .gtoreq.0.2 ng/mL within 2.5 minutes in said patient.

38. The pharmaceutical formulation of claim 33, which yields, when intranasally administered to a patient, a naloxone plasma concentration of .gtoreq.1 ng/mL within 5 minutes in said patient.

39. The pharmaceutical formulation of claim 33, which yields, when intranasally administered to a patient, a naloxone plasma concentration of .gtoreq.3 ng/mL within 10 minutes in said patient.

40. The pharmaceutical formulation of claim 30, which yields, when intranasally administered to a patient, a naloxone T.sub.max of less than 30 minutes.

41. The pharmaceutical formulation of claim 30, which yields, when intranasally administered to a patient, a naloxone T.sub.max of less than 25 minutes.

42. The pharmaceutical formulation of claim 30, which yields, when intranasally administered to a patient, a naloxone T.sub.max of less than 20 minutes.

43. The pharmaceutical formulation of claim 33, which yields, when intranasally administered to a patient, a naloxone T.sub.max of less than 30 minutes.

44. The pharmaceutical formulation of claim 33, which yields, when intranasally administered to a patient, a naloxone T.sub.max of less than 25 minutes.

45. The pharmaceutical formulation of claim 33, which yields, when intranasally administered to a patient, a naloxone T.sub.max of less than 20 minutes.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.